Ultragenyx PharmaceuticalvsThermo Fisher Scientific

RARE and TMO stock compared: price, dividend, valuation and results, from SEC filings.

RARE

Ultragenyx Pharmaceutical Inc.

$16.09

Value $1.6B

+0.06%
RARE's page

TMO

Thermo Fisher Scientific Inc

$698.93

Value $260B

-0.24%
TMO's page

Ultragenyx Pharmaceutical (RARE) has a market value of $1.6B and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, RARE moved -51.4% and TMO +21.2%. Dividend yield: RARE none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    RARE$1.6B

    TMO$260B

    TMO is 158 times RARE

  • Revenue, 12 months

    RARE$730M

    TMO$47.4B

    TMO is 65 times RARE

  • Net income, 12 months

    RARE-$524M

    TMO$7.1B

  • Operating margin

    RARE-64.0%

    TMO17.9%

    81.9 points apart

  • ROIC

    RARE–

    TMO8.2%

  • P/E

    RARE–

    TMO36.7

  • Dividend yield

    RARE0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    RARE-80.0%

    TMO+12.1%

    92.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

RARE-80.0%

TMO+12.1%

5010020222023202420252026
Returns by period
PeriodRAREWith dividendsTMOWith dividends
1 year since November 14, 2025-51.4%Price -51.4%+21.2%Price +20.8%
3 years since November 16, 2023-58.7%-25.5% a yearPrice -58.7%+49.4%+14.3% a yearPrice +47.9%
5 years since November 15, 2021-80.0%-27.5% a yearPrice -80.0%+12.1%+2.3% a yearPrice +10.5%
10 years since November 16, 2016-79.3%-14.6% a yearPrice -79.3%+380.9%+17.0% a yearPrice +367.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

RAREUltragenyx PharmaceuticalTMOThermo Fisher Scientific

Valuation

RARETMO
Valuation
Price$16.09$698.93
Market value$1.6B$260B
Enterprise value (EV)$1.4B$295B
P/E–36.7
P/E, 5-year median–32.7
P/B–4.7
EV/EBIT–34.8
Free cash flow yield–2.9%

Results and growth

RARETMO
Results and growth
Revenue, 12 months$730M$47.4B
Net income, 12 months-$524M$7.1B
Free cash flow, 12 months-$442M$7.6B
Earnings per share, 12 months-$5.18$18.96
Revenue growth, year on year20.2%3.9%
Revenue growth a year, past+20.0%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

RARETMO
Margins and returns on capital
Gross margin––
Operating margin-64.0%17.9%
Net margin-71.8%14.9%
ROIC–8.2%
ROE–13.4%

Balance sheet

RARETMO
Balance sheet
Cash$266M$6.1B
Total debt$36M$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

RARETMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: RARE or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Ultragenyx Pharmaceutical or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 158.3 times Ultragenyx Pharmaceutical ($1.6B), at today's prices.

How did RARE and TMO stock do over the last 10 years?

Since November 16, 2016, RARE's price moved -79.3% and TMO's +367.5%. With dividends: RARE -79.3% (-14.6% a year), TMO +380.9% (+17.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, RARE or TMO?

The dividend yield at today's price is none for Ultragenyx Pharmaceutical and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Ultragenyx Pharmaceutical or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -71.8% for Ultragenyx Pharmaceutical and 14.9% for Thermo Fisher Scientific, and the operating margin -64.0% and 17.9%. Revenue was $730M and $47.4B.

Which is the better investment, Ultragenyx Pharmaceutical or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.